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Background: As regulators of gene expression, microRNAs (miRNAs) play a key role in the transcriptional networks
of the developing human brain. Circulating miRNAs in the serum and plasma are remarkably stable and are
suggested to have promise as noninvasive biomarkers for neurological and neurodevelopmental disorders. We
examined the serum expression profiles of neurologically relevant miRNAs in autism spectrum disorder (ASD), a
complex neurodevelopmental disorder characterized by multiple deficits in communication, social interaction and
behavior.
Methods: Total RNA, including miRNA, was extracted from the serum samples of 55 individuals with ASD and 55
age- and sex-matched control subjects, and the mature miRNAs were selectively converted into cDNA. Initially, the
expression of 125 mature miRNAs was compared between pooled control and ASD samples. The differential
expression of 14 miRNAs was further validated by SYBR Green quantitative PCR of individual samples. Receiver-operating
characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of miRNAs. The target genes and
pathways of miRNAs were predicted using DIANA mirPath software.
Results: Thirteen miRNAs were differentially expressed in ASD individuals compared to the controls. MiR-151a-3p,
miR-181b-5p, miR-320a, miR-328, miR-433, miR-489, miR-572, and miR-663a were downregulated, while miR-101-3p,
miR-106b-5p, miR-130a-3p, miR-195-5p, and miR-19b-3p were upregulated. Five miRNAs showed good predictive
power for distinguishing individuals with ASD. The target genes of these miRNAs were enriched in several crucial
neurological pathways.
Conclusions: This is the first study of serum miRNAs in ASD individuals. The results suggest that a set of serum miRNAs
might serve as a possible noninvasive biomarker for ASD.
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Autism spectrum disorder (ASD) refers to a group of
heterogeneous neurodevelopmental disorders characte-
rized by impairments in communication and social inter-
action, and restricted, repetitive and stereotypic patterns
of behavior [1]. According to a recent estimate, 1 in 88
individuals has ASD [2]. ASD is largely genetic in origin,
with most data supporting a polygenic epistatic model
[3,4]. However, owing to the heterogeneous nature of
this disorder, classical genetic studies have not necessarily
been successful in identifying suitable candidate genes for
ASD. In addition to the genetic factors, environmental fac-
tors also play a vital role in predisposing individuals to* Correspondence: k-suzuki@hama-med.ac.jp
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article, unless otherwise stated.ASD [5]. In recent years, epigenetic mechanisms, which
act at the interface of genes and the environment, have
been identified as a potential contributor to the pathogen-
esis of several neurodevelopmental abnormalities such as
ASD [6]. Epigenetic factors control heritable changes in
gene expression without changing the DNA sequence [7].
MicroRNAs (miRNAs) have recently emerged as promi-
nent epigenetic regulators of a variety of cellular processes,
including differentiation, apoptosis and metabolism [8].
miRNAs are a class of small (approximately 21 nucleotides)
noncoding transcripts that can modulate cellular messenger
RNA (mRNA) and protein levels by interacting with
specific mRNAs, usually at the 3′ untranslated region
(UTR), resulting in mRNA degradation or repression of
translation [9,10], through partial sequence complementa-
tion [11]. MiRNAs are abundantly present in the brain,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of brain function, particularly in neuronal plasticity and
neuronal development [12].
So far, three studies have determined the expression of
miRNAs in lymphoblastoid cell cultures of ASD patients,
and one study has identified dysregulated miRNAs in the
cerebellar cortex of ASD patients. Abu-Elneel et al. first
observed an altered expression of miRNAs and their
brain-specific targets in the postmortem cerebellar cor-
tices of autism subjects [13]. Studies in lymphoblastoid
cells have implicated brain-related miRNAs and their tar-
gets in the pathophysiological conditions underlying aut-
ism [14-16].
MiRNAs have also been found to be present in the
extracellular fluids such as plasma, serum, saliva, and
urine of humans in detectable concentrations [17-20].
In particular, serum miRNAs, which may be derived from
circulating blood cells, are known to be remarkably stable,
reproducible and resistant to the actions of RNase [21],
suggesting the potential efficacy of serum miRNAs as
noninvasive biomarkers for ASD. Therefore, in the
present study we performed miRNA expression profil-
ing of serum samples from individuals with ASD who
had never received drug treatment.
Methods
This study was approved by the Ethics Committee of
Hamamatsu University School of Medicine, Japan. A de-
tailed description of the study was given to all participants
and their parents before enrollment. Blood samples were
collected from the donors after obtaining written informed
consent.
Subjects
In this study, we included 55 subjects with ASD (age =
11.29 ± 2.45 years (mean ± SD); range = 6 to 16 years; 48
males and 7 females) and 55 age- and sex-matched typically
developed control subjects (age = 11.3 ± 2.37; range = 6 to
16; 41 males and 14 females). There were no significance
differences in the age (P = 0.9685) or sex (P = 0.089) distri-
bution between the control and ASD groups (Table 1). AllTable 1 Clinical and/demographic variables of individuals wit
Clinical/demographic Autism (n = 55)





Domain A score, social 17.7 ± 7.62 (10 to 29)
Domain BV score, communication 12.8 ± 5.62 (8 to 25)
Domain C score, stereotype 4.1 ± 2.84 (3 to 12)
Values are expressed as the mean ± SD (range).at-test, bchi-square test. ADI-R, Autismof the participants were Japanese. The diagnosis of ASD
was made on the basis of the Diagnostic and Statistical
Manual, Fourth Edition, Text Revision (DSM-IV-TR;
American Psychiatric Association, 2000) criteria. The
Autism Diagnostic Interview-Revised (ADI-R) [22] was
conducted by experienced child psychiatrists who are li-
censed to use the Japanese version of the ADI-R. Partici-
pants having comorbid psychiatric illnesses were excluded
by means of the Structured Clinical Interview for DSM-IV
(SCID) [23]; any additional psychiatric or neurological
diagnosis was also excluded. None of the participants had
received any drug treatment for ASD.
Typically developed individuals (control group) were
recruited through advertisements in local newspapers.
Control group participants underwent a comprehensive
assessment of their medical history; those with neurological
or other medical disorders were excluded. The SCID was
also conducted to screen all participants for any past or
present mental illness. None of the control participants
were diagnosed with any neuropsychiatric condition.
Serum separation
Blood samples were collected between 11:00 am and
noon from each subject by venipuncture, and the samples
were kept for 30 min at room temperature. All protocols
for serum separation were completed within 1 h of drawing
blood. Serum was separated by centrifugation at 3,500 rpm
for 10 min at room temperature. Hemolyzed samples were
excluded from the study at this stage. The clear supernatant
was collected into RNase/DNase-free microfuge tubes in
200 μl aliquots and stored at −80°C until use.
RNA extraction and cDNA synthesis
Total RNA, including miRNA, was extracted from
200 μl serum by using an MiRNeasy Serum/Plasma Kit
(QIAGEN GmbH, Hilden, Germany) in accordance with
the manufacturer’s protocol. Briefly, five volumes of
QIAzol lysis reagent was added to the sample; a syn-
thetic spike-in control, Caenorhabditis elegans miR-39
(1.6 × 108 copies/μl), was added to the lysed samples for
internal normalization. After adding an equal volume ofh autism and of control subjects
Control (n = 55) P value
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12,000 g at 4°C. The upper aqueous phase was mixed
with 1.5 volumes of 100% ethanol, transferred to a spin
column, centrifuged, washed, and eluted in 14 μl RNase-
free water.
Two microliters of each RNA sample was used for
cDNA synthesis using the miScript ІІ RT kit (QIAGEN).
The reverse-transcription reaction mix (20 μl) was pre-
pared using Hispec buffer (for selective conversion of
mature miRNAs into cDNA), nucleics mix, RT mix and
RNase-free water. The reaction mixture was incubated
for 60 min at 37°C, followed by denaturation for 5 min
at 95°C. Each cDNA was further diluted to 220 μl with
RNase-free water and stored at −20°C until use.
microRNA screening
Initial screening was done using the Human Neurological
Development & Disease miRNA PCR array (SABios-
ciences, Frederick, MD, USA), which contains 84
miRNA assays, and a custom-made array (SABiosciences)
with 41 miRNA assays (see Additional files 1 and 2). For
this purpose, 40 samples were chosen from 55 ASD
subjects at random, and 40 matched control samples
were selected. All the miRNAs included in the arrays
have previously been reported to play a role in various
aspects of brain development and function and/or in
several neuropsychiatric conditions such as ASD. Both
arrays included C. elegans miR-39 primer assays for
internal normalization, snoRNA/snRNA (SNORD48,
SNORD61, SNORD68, SNORD72, SNORD95, SNORD96A
and RNU6-2) PCR control assays, positive PCR control
(PPC) assays, and miRNA reverse transcription control
(miRTC) assays.
RNA from age- and sex-matched control (n = 40) and
ASD (n = 40) samples were pooled separately to generate
four pools per group, with each pool consisting of 10
samples. Then, cDNA prepared from 3 μl of the pooled
RNA was used for array screening. The expression of
miRNAs was detected and quantified by means of SYBR
Green reverse-transcription quantitative PCR performed
with an ABI PRISM 7900 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA).
Normalization
The data sets were first calibrated using a C. elegans
miR-39 assay, which detected the spike-in control that
was added to the serum samples during RNA extraction.
This calibration would have resolved any differences in
recovery that may have occurred during the purification
procedure, or any differences in amplification efficiency.
Due to the very low expression of snoRNA/snRNA PCR
controls in the serum, three alternate normalization strat-
egies, as recommended by the manufacturer, were used
for data normalization. These were (i) normalization tothe whole plate Ct mean, (ii) normalization to the plate Ct
mean of commonly expressed (Ct < 30) miRNAs, and (iii)
normalization to the Ct mean of at least four invariant miR-
NAs with little (<1) Ct variation between samples. In the
third strategy, miR-125b-5p, miR-126-5p, miR-140-5p and
miR-191-5p were chosen for the data normalization of the
neurological array, whereas miR-103a-3p, miR-21-5p, miR-
23a-3p, and miR-25-3p were chosen for the custom array.
Consistent results were obtained using all three strategies.
Data analysis
An Excel-based miRNA PCR Array Data Analysis tool
(SABiosciences; http://pcrdataanalysis.sabiosciences.com/
mirna) was used for data analysis. SABiosciences makes use
of the ΔΔCt method for the relative quantification of miR-
NAs. Student’s t-test was used to examine any differential
expression of miRNAs between the ASD and control
groups; values of P <0.05 were considered to indicate sta-
tistical significance (GEO Accession Number: GSE58850).
Quantitative reverse-transcription PCR
SYBR Green qPCR, performed on an ABI PRISM 7900
Sequence Detection System (Applied Biosystems), was
used for the validation of differentially expressed miR-
NAs (the accession ID and mature miRNA sequence are
given in Additional file 3). In this validation experiment,
all the samples (55 subjects with autism and 55 controls)
were examined individually. Ten microliters of qPCR re-
action mixture was prepared with a universal primer,
primer assay and RNase-free water. All the qPCR reac-
tions were performed in triplicate with the following
cycling conditions: 95°C→ 15 min, followed by 40 cycles
of 94°C→ 15 sec, 55°C→ 30 sec and 70°C→ 30 sec.
The Ct values of nine miRNAs (miR-101-3p, miR-
106b-5p, miR-151a-3p, miR-195-5p, miR-19b-3p, miR-
27a-3p, miR-320a, miR-328, and miR-489) were in the
range of 25–30, while the remaining five miRNAs (miR-
130a-3p, miR-181b-5p, miR-433, miR-572, and miR-
663a) had Ct values in the range of 30 to 35.
Normalization
A randomly chosen control sample was amplified in
each plate and used as an interplate calibrator to correct
for the experimental differences among consecutive PCR
runs. The qPCR data was first subjected to interplate
calibration, followed by C. elegans miR-39 (detection of
the spike-in control) calibration. The expression of miR-
16, an miRNA highly abundant in the red blood cells,
was analyzed in each sample to examine the extent of
hemolysis in the serum. Any sample that showed signi-
ficant hemolysis (the value of Ct invariant miRNA - Ct
miR16 was greater than 5) was omitted from further
analyses. Finally, the qPCR data were normalized to the
average of three invariantly expressed miRNAs, let-7a, miR-
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miR-103a-3p were selected on the basis of their perform-
ance as invariant miRNAs in the neurological array and
custom array, respectively, while let-7a has been widely re-
ported as an invariant miRNA in blood. The fold change in
gene expression between the control and ASD groups was
determined by the ΔΔCt method of relative quantification.
Statistical analysis
All statistical calculations were performed with PASW
Statistics 18 software (IBM, Tokyo, Japan). Student’s t-
test and chi-square test were used to examine any vari-
ability in the distribution of age and sex, respectively,
across the control and ASD groups. Any differential
expression of miRNAs between the control and ASD
groups was determined by Mann–Whitney test. The
relationship between the expression of miRNA and
ADI-R subscores was evaluated by Spearman’s correl-
ation coefficient. Analysis of covariance (ANCOVA)
was used to control for potential covariates such as age
and sex. Receiver Operating Characteristics (ROC)
curve analysis was used for evaluating the diagnostic
power of miRNAs.
Enrichment pathway analysis and target gene prediction
The DIANA mirPath v2.0 (http://diana.cslab.ece.ntua.gr/
pathways/) functional annotation tool was used to predictFigure 1 Results from preliminary screening experiments. The Ct value
strategies. miR-151a-3p, miR-181b-5p, miR-320a, miR-328, miR-433, miR-489
miR-106b-5p, miR-19b-3p, miR-195-5p, miR-130a-3p and miR-27a-3p were u
compared to controls.the target genes and altered pathways of differentially
expressed miRNAs. This tool predicts the miRNA tar-
gets based on DIANA-microT-CDS and/or experi-
mentally verified targets from TarBase v6 (manually




Ct values of the PPC controls were 19 ± 2 across all sam-
ples, indicating the uniformity of reaction conditions.
The differences between the Ct values of PPC and
miRTC were calculated as <7, indicating that there was
no inhibition of the reverse-transcription reaction.
In the preliminary array screening, we observed an al-
tered expression of 14 miRNAs in the ASD samples
compared to those of controls (Figure 1). MiR-151a-3p,
miR-181b-5p, miR-320a, miR-328, miR-433, miR-489,
miR-572 and miR-663a were downregulated, while miR-
101-3p, miR-106b-5p, miR-19b-3p, miR-195-5p, miR-
130a-3p and miR-27a-3p were upregulated.
Confirmation with quantitative PCR
The differential expression of the 14 miRNAs was fur-
ther validated by SYBR Green qPCR. We observed
consistent results for all miRNAs except miR-27a-3p
(Figure 2). miR-151a-3p (ΔΔCt = −2.01, P = 8.29E-06),s obtained were normalized and calculated by three different
, miR-572 and miR-663a were downregulated while miR-101-3p,
pregulated. Bars represent the fold change in subjects with autism as
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(ΔΔCt = −2.47, P = 5.02E-12), miR-328 (ΔΔCt = −2.28,
P = 4.33E-06), miR-433 (ΔΔCt = −2.33, P = 0.0001), miR-
489 (ΔΔCt = −2.10, P = 1.25E-06), miR-572 (ΔΔCt = −2.47,
P = 2.66E-08) and miR-663a (ΔΔCt = −2.06, P = 0.00002)
were downregulated, while miR-101-3p (ΔΔCt = 1.43, P =
0.003), miR-106b-5p (ΔΔCt = 1.30, P = 0.008), miR-130a-
3p (ΔΔCt = 2.35, P = 1.89E-09), miR-195-5p (ΔΔCt = 1.43,
P = 0.0016) and miR-19b-3p (ΔΔCt = 1.87, P = 6.88E-09)
were upregulated in the ASD individuals.
When the samples from the ASD individuals were ex-
amined for correlations between the expression of each
miRNA and each of the three domains assessed by ADI-
R (Domain A score, social; Domain score BV, communi-
cation; Domain C score, stereotype), none of the miRNA
expressions was correlated with any of the domains (see
Additional file 4).
The effects of age and sex on miRNA expression were
examined by ANCOVA. The difference in the expression of
miRNAs between the ASD and control groups remained
significant even after adjusting for the effects of age and sex
(see Additional file 5).Figure 2 Scatter plot showing the differential expression of 13 microReceiver operating characteristic analysis
Receiver operating characteristic (ROC) curve analysis
was used to evaluate the predictive power of differentially
expressed miRNAs to distinguish between ASD indivi-
duals and controls. The analysis showed significant diag-
nostic values of these 13 differentially expressed miRNAs
for ASD (Figure 3). High values for sensitivity, specificity
and the area under the curve (AUC) were observed for five
miRNAs: miR-181b-5p, miR-320a, miR-572, miR-130a-3p
and miR-19b-3p (see Additional file 6).
Enrichment pathway analysis and target gene prediction
Using DIANA mirPath software, we found that the pre-
dicted target genes of the differentially expressed miR-
NAs could be involved in diverse vital neurological
pathways (Figure 4). By a thorough analysis of the target
genes and the pathways involving them, a total of 600
predicted genes and 18 neurological pathways were
found (see Additional file 7). The top ten neurological
pathways were those involved in axon guidance, TGF-
beta signaling, MAPK signaling, adherens junction, regu-
lation of actin cytoskeleton, oxidative phosphorylation,RNAs in autistic subjects.
Figure 3 Receiver operating characteristic (ROC) curve of 13 microRNAs. AUC, area under the ROC curve; SEN, sensitivity; SPE, specificity.
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Wnt signaling. No specific pathways were observed for
miR-572.
Discussion
This is the first report on serum miRNAs in subjects
with ASD. Altered expression of 13 miRNAs (downregu-
lation of 8 miRNAs; upregulation of 5 miRNAs) was ob-
served in our ASD subjects. Previous reports have
shown a differential expression pattern of miRNAs in
the postmortem brain [13] and in the lymphoblastoid
cell lines of ASD individuals [14-16]. The results of the
present and previous studies are summarized in Table 2,
in which hsa-miR-181b-5p, hsa-miR-195-5p, hsa-miR-
320a and hsa-miR-328 showed the same direction ofregulation as in the brain [13] and lymphoblasts [14-16],
while hsa-miR-106b-5p, hsa-miR-19b-30 and hsa-miR-
663a did not. The reason for the latter differences in
miRNA expression between the present and previous re-
sults is not known. The fact that the direction of alter-
ation in the expression of hsa-miR-106b-5p in this study
was the opposite of that reported in the previous post-
mortem study [13] suggests that the serum level of
certain miRNAs may not reflect that in the brain, and
thus that our findings should be treated with caution.
However, it was interesting that hsa-miR-181b-5p and
hsa-miR-328 in serum showed the same direction of regu-
lation as in the brain. As mentioned above, serum miRNA
expression is very stable, reproducible and resistant to
RNase action [21]. In addition, an ANCOVA showed
Figure 4 Neurologically relevant pathways (predicted by DIANA mirPath) of the target genes of differentially expressed microRNAs.
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influence the results observed here. Therefore, hsa-miR-
181b-5p and hsa-miR-328 in serum may become per-
ipheral biomarkers reflecting the miRNA expression
profile of individuals with ASD.
ROC curve analyses showed significant diagnostic
values of 13 differentially expressed miRNAs for ASD
(Figure 3). High values for sensitivity, specificity and
area under the curve (AUC) were observed for five miR-
NAs: miR-181b-5p, miR-320a, miR-572, miR-130a-3p
and miR-19b-3p (see Additional file 6). Therefore, these
five miRNAs may be potential candidates for circulating
miRNA-based prediction of ASD.
MiRNA can influence gene silencing via translational
repression or mRNA degradation [24]. This mRNA
destabilization may alter several downstream pathways
and induce several noticeable effects [25]. A number of
neurologically relevant pathways and target genes wereTable 2 Comparison of the results of the present study and p








(↑), upregulated, (↓), downregulated.identified by our enrichment analysis, with most of the
target genes being involved in multiple pathways. Col-
lectively, these results predicted several neurologically
relevant canonical pathways for the target genes of the
five miRNAs (miR-130a-3p, miR-19b-3p, miR-320a,
miR181b-5p, and miR-572) that showed a good discrim-
inative power in ROC analysis. Most of these genes and
pathways have already been implicated in the pathogen-
esis of ASD [4,26-30].
The differentially expressed miRNAs in this study,
which included miR-101, miR-106b, miR-130a, miR-151a,
miR181b, miR-328, miR-433, miR-489 and miR-572, were
previously reported to have altered expression in schizo-
phrenia [31-35], supporting the contention that ASD
and schizophrenia share common neurobiological fea-
tures [36].
The detection of clinically useful noninvasive bio-
markers that could allow early intervention for ASD isrevious autism microRNA studies
rt Type of sample Reference
Brain [13]
Brain, lymphoblastoid cell line [13,16]
Lymphoblastoid cell line [15]
Lymphoblastoid cell line [14]
Lymphoblastoid cell line [14]
Brain [13]
Lymphoblastoid cell line [14]
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ward this goal, our results suggest that serum miRNAs
could be potential peripheral biomarkers of ASD. A limi-
tation of this study is that the samples came from ASD
individuals ranging from 6 to 16 years old, although
ASD is an early-onset disorder. Therefore, to accurately
evaluate the diagnostic power of circulating miRNAs in
ASD, further studies on subjects of lower age will be ne-
cessary. Another limitation of the study is that we used
the same sample set in both the screening and valid-
ation. It would have been more informative if we had
screened an independent sample set.
Conclusions
This preliminary noninvasive study found a set of signifi-
cantly differentially expressed miRNAs in the sera of
children with ASD. The predicted target genes of these
miRNAs were found to be associated with neurologically
relevant pathways and functions.
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